These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 32631974)

  • 1. TRAF3 Modulation: Novel Mechanism for the Anti-inflammatory Effects of the Vitamin D Receptor Agonist Paricalcitol in Renal Disease.
    Rayego-Mateos S; Morgado-Pascual JL; Valdivielso JM; Sanz AB; Bosch-Panadero E; Rodrigues-Díez RR; Egido J; Ortiz A; González-Parra E; Ruiz-Ortega M
    J Am Soc Nephrol; 2020 Sep; 31(9):2026-2042. PubMed ID: 32631974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling.
    Tan X; Wen X; Liu Y
    J Am Soc Nephrol; 2008 Sep; 19(9):1741-52. PubMed ID: 18525004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of vitamin D/VDR nuclear translocation in down-regulation of NF-κB/NLRP3/caspase-1 axis in lupus nephritis.
    Huang J; An Q; Ju BM; Zhang J; Fan P; He L; Wang L
    Int Immunopharmacol; 2021 Nov; 100():108131. PubMed ID: 34536747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renoprotective effect of paricalcitol via a modulation of the TLR4-NF-κB pathway in ischemia/reperfusion-induced acute kidney injury.
    Lee JW; Kim SC; Ko YS; Lee HY; Cho E; Kim MG; Jo SK; Cho WY; Kim HK
    Biochem Biophys Res Commun; 2014 Feb; 444(2):121-7. PubMed ID: 24434153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D receptor activation protects against lipopolysaccharide-induced acute kidney injury through suppression of tubular cell apoptosis.
    Du J; Jiang S; Hu Z; Tang S; Sun Y; He J; Li Z; Yi B; Wang J; Zhang H; Li YC
    Am J Physiol Renal Physiol; 2019 May; 316(5):F1068-F1077. PubMed ID: 30864841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D/VDR attenuate cisplatin-induced AKI by down-regulating NLRP3/Caspase-1/GSDMD pyroptosis pathway.
    Jiang S; Zhang H; Li X; Yi B; Huang L; Hu Z; Li A; Du J; Li Y; Zhang W
    J Steroid Biochem Mol Biol; 2021 Feb; 206():105789. PubMed ID: 33259938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paricalcitol attenuates lipopolysaccharide-induced myocardial inflammation by regulating the NF-κB signaling pathway.
    Lee AS; Jung YJ; Thanh TN; Lee S; Kim W; Kang KP; Park SK
    Int J Mol Med; 2016 Apr; 37(4):1023-9. PubMed ID: 26954764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paricalcitol Inhibits Aldosterone-Induced Proinflammatory Factors by Modulating Epidermal Growth Factor Receptor Pathway in Cultured Tubular Epithelial Cells.
    Morgado-Pascual JL; Rayego-Mateos S; Valdivielso JM; Ortiz A; Egido J; Ruiz-Ortega M
    Biomed Res Int; 2015; 2015():783538. PubMed ID: 26064952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease.
    Andress D
    Drugs; 2007; 67(14):1999-2012. PubMed ID: 17883284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specificity of TRAF3 in its negative regulation of the noncanonical NF-kappa B pathway.
    He JQ; Saha SK; Kang JR; Zarnegar B; Cheng G
    J Biol Chem; 2007 Feb; 282(6):3688-94. PubMed ID: 17158868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stem cells and a vitamin D receptor agonist additively suppress T helper 17 cells and the related inflammatory response in the kidney.
    Duffy MM; McNicholas BA; Monaghan DA; Hanley SA; McMahon JM; Pindjakova J; Alagesan S; Fearnhead HO; Griffin MD
    Am J Physiol Renal Physiol; 2014 Dec; 307(12):F1412-26. PubMed ID: 25339699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D modulates tissue factor and protease-activated receptor 2 expression in vascular smooth muscle cells.
    Martinez-Moreno JM; Herencia C; Montes de Oca A; Muñoz-Castañeda JR; Rodríguez-Ortiz ME; Díaz-Tocados JM; Peralbo-Santaella E; Camargo A; Canalejo A; Rodriguez M; Velasco-Gimena F; Almaden Y
    FASEB J; 2016 Mar; 30(3):1367-76. PubMed ID: 26700731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M; Brancaccio D
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of vitamin D receptor attenuates high glucose-induced cellular injury partially dependent on CYP2J5 in murine renal tubule epithelial cell.
    Liu Y; Li L; Yi B; Hu ZX; Li AM; Yang C; Zheng L; Zhang H
    Life Sci; 2019 Oct; 234():116755. PubMed ID: 31415769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy.
    Sanchez-Niño MD; Bozic M; Córdoba-Lanús E; Valcheva P; Gracia O; Ibarz M; Fernandez E; Navarro-Gonzalez JF; Ortiz A; Valdivielso JM
    Am J Physiol Renal Physiol; 2012 Mar; 302(6):F647-57. PubMed ID: 22169009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory profile of paricalcitol in kidney transplant recipients.
    Donate-Correa J; Henríquez-Palop F; Martín-Núñez E; Hernández-Carballo C; Ferri C; Pérez-Delgado N; Muros-de-Fuentes M; Mora-Fernández C; Navarro-González JF
    Nefrologia; 2017; 37(6):622-629. PubMed ID: 28623033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting TRAF3 signaling protects against hepatic ischemia/reperfusions injury.
    Hu J; Zhu XH; Zhang XJ; Wang PX; Zhang R; Zhang P; Zhao GN; Gao L; Zhang XF; Tian S; Li H
    J Hepatol; 2016 Jan; 64(1):146-59. PubMed ID: 26334576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired arterial vitamin D signaling occurs in the development of vascular calcification.
    Lim K; Molostvov G; Lubczanska M; Fletcher S; Bland R; Hiemstra TF; Zehnder D
    PLoS One; 2020; 15(11):e0241976. PubMed ID: 33211721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphocyte and monocyte vitamin D receptor expression during paricalcitol or calcitriol treatments in patients with stage 5 chronic kidney disease.
    Sözel H; Köksoy S; Ozdem S; Yılmaz F; Bora F; Ersoy FF
    Int Urol Nephrol; 2020 Aug; 52(8):1563-1570. PubMed ID: 32405698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells.
    Sochorová K; Budinský V; Rozková D; Tobiasová Z; Dusilová-Sulková S; Spísek R; Bartůnková J
    Clin Immunol; 2009 Oct; 133(1):69-77. PubMed ID: 19660988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.